Warning! GuruFocus detected
2 Severe warning signs
with IKT.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Inhibikase Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US45719W2052
Share Class Description:
IKT: Ordinary SharesDescription
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 878.78 | |||||
| Equity-to-Asset | 0.96 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 37.2 | |||||
| 3-Year EPS without NRI Growth Rate | 38 | |||||
| 3-Year FCF Growth Rate | 44.4 | |||||
| 3-Year Book Growth Rate | -46.9 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 40.36 | |||||
| 9-Day RSI | 45.08 | |||||
| 14-Day RSI | 46.59 | |||||
| 3-1 Month Momentum % | -15.74 | |||||
| 6-1 Month Momentum % | -3.41 | |||||
| 12-1 Month Momentum % | 12.5 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 26.37 | |||||
| Quick Ratio | 26.37 | |||||
| Cash Ratio | 26.12 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -154.8 | |||||
| Shareholder Yield % | -69.17 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -117.42 | |||||
| ROA % | -100.16 | |||||
| ROIC % | -2901.85 | |||||
| 3-Year ROIIC % | -2346.86 | |||||
| ROC (Joel Greenblatt) % | -12808.69 | |||||
| ROCE % | -121.8 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.47 | |||||
| Price-to-Tangible-Book | 1.47 | |||||
| EV-to-EBIT | -1.87 | |||||
| EV-to-Forward-EBIT | -0.08 | |||||
| EV-to-EBITDA | -1.87 | |||||
| EV-to-Forward-Revenue | 1358.04 | |||||
| EV-to-FCF | -2.79 | |||||
| Price-to-Net-Current-Asset-Value | 1.47 | |||||
| Price-to-Net-Cash | 1.49 | |||||
| Earnings Yield (Greenblatt) % | -53.48 | |||||
| FCF Yield % | -12.81 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers